Compare Stocks

→ Missed NVDA? Buy this AI stock NOW (From Chaikin Analytics) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX BriaCell Therapeutics	$2.25 -0.4%	$2.58	$2.01 ▼ $7.59	$35.96M	1.14	36,815 shs	6,158 shs
STSA Satsuma Pharmaceuticals	$1.10 -0.9%	$1.08	$0.59 ▼ $8.08	$36.47M	0.1	701,788 shs	1.83 million shs
UNCY Unicycive Therapeutics	$1.13 +4.6%	$1.29	$0.47 ▼ $1.82	$42.49M	2.72	454,206 shs	280,362 shs
XLO Xilio Therapeutics	$1.18 -6.3%	$1.03	$0.49 ▼ $3.25	$43.56M	-0.13	266,882 shs	230,498 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX BriaCell Therapeutics	0.00%	-0.44%	-15.73%	-42.60%	-68.35%
STSA Satsuma Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+3.77%
UNCY Unicycive Therapeutics	0.00%	+0.89%	-9.60%	+1.80%	-24.67%
XLO Xilio Therapeutics	0.00%	0.00%	-13.24%	+87.30%	-63.13%

READ THIS – If You Missed Out On The AI Boom (Ad)

Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”

Click on Adam's shiny forehead for more details.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCTX BriaCell Therapeutics	2.2341 of 5 stars	3.5	3.0	0.0	0.0	3.3	1.7	0.0
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	2.9103 of 5 stars	3.5	3.0	0.0	0.0	3.2	2.5	0.6
XLO Xilio Therapeutics	0.7702 of 5 stars	0.0	2.0	0.0	0.0	2.5	2.5	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCTX BriaCell Therapeutics	3.00	Buy	$18.00	700.00% Upside
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.00	Buy	$5.30	369.03% Upside
XLO Xilio Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings

Latest STSA, XLO, BCTX, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00
4/4/2024	UNCY Unicycive Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$9.00
4/1/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
3/14/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
3/5/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
2/14/2024	UNCY Unicycive Therapeutics	Noble Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00

(Data available from 5/12/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCTX BriaCell Therapeutics	N/A	N/A	N/A	N/A	($0.24) per share	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
UNCY Unicycive Therapeutics	$680K	62.50	N/A	N/A	($0.11) per share	-10.27
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	$1.34 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCTX BriaCell Therapeutics	-$20.30M	-$1.68	N/A	N/A	N/A	N/A	N/A	-57.48%	6/12/2024 (Estimated)
STSA Satsuma Pharmaceuticals	-$70.06M	-$2.01	N/A	N/A	N/A	N/A	-115.24%	-102.26%	N/A
UNCY Unicycive Therapeutics	-$30.54M	-$1.55	N/A	N/A	N/A	N/A	N/A	-96.37%	5/21/2024 (Estimated)
XLO Xilio Therapeutics	-$76.40M	-$2.78	N/A	N/A	N/A	N/A	-126.55%	-89.20%	5/14/2024 (Estimated)

Latest STSA, XLO, BCTX, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/1/2024	Q4 2023	XLO Xilio Therapeutics	N/A	-$0.64	-$0.64	-$0.64	N/A	N/A
3/28/2024	Q4 2023	UNCY Unicycive Therapeutics	-$0.18	-$0.16	+$0.02	-$0.16	N/A	N/A
3/18/2024	Q2 2024	BCTX BriaCell Therapeutics	-$0.20	-$0.71	-$0.51	-$0.71	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCTX BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCTX BriaCell Therapeutics	N/A	2.99	2.99
STSA Satsuma Pharmaceuticals	N/A	7.44	7.44
UNCY Unicycive Therapeutics	N/A	0.76	0.76
XLO Xilio Therapeutics	N/A	3.02	3.02

Ownership

Institutional Ownership

Company	Institutional Ownership
BCTX BriaCell Therapeutics	15.42%
STSA Satsuma Pharmaceuticals	93.26%
UNCY Unicycive Therapeutics	40.42%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
BCTX BriaCell Therapeutics	21.77%
STSA Satsuma Pharmaceuticals	31.20%
UNCY Unicycive Therapeutics	42.00%
XLO Xilio Therapeutics	4.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BCTX BriaCell Therapeutics	16	15.98 million	12.50 million	Optionable
STSA Satsuma Pharmaceuticals	21	33.15 million	22.81 million	Not Optionable
UNCY Unicycive Therapeutics	12	37.61 million	21.81 million	Not Optionable
XLO Xilio Therapeutics	73	36.91 million	35.21 million	Not Optionable

STSA, XLO, BCTX, and UNCY Headlines

Source	Headline
	Xilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61 msn.com - April 17 at 6:22 PM
	Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why zacks.com - April 16 at 10:16 AM
	3 Biotech Stocks to Invest In Right Now for Long-Term Gains stocknews.com - April 12 at 1:00 PM
	Gilead Sciences, Inc. Buys 485,250 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock insidertrades.com - April 4 at 6:16 AM
	XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023 investorplace.com - April 2 at 12:01 AM
	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results globenewswire.com - April 1 at 4:05 PM
	Sizing Your Penny Stocks Position, 3 Tips pennystocks.com - March 31 at 6:26 AM
	Gilead Sciences Licenses Xilio Therapeutics' IL-12 Molecule XTX301 precisionmedicineonline.com - March 29 at 6:33 PM
	Xilio Shares Take Flight Premarket After Gilead Deal marketwatch.com - March 29 at 8:08 AM
	Why Is Xilio Therapeutics (XLO) Stock up 168% Today? investorplace.com - March 28 at 11:10 AM
	Xilio Therapeutics Plans Private Placement, Job Cuts marketwatch.com - March 28 at 10:08 AM
	Xilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of Jobs markets.businessinsider.com - March 28 at 10:08 AM
	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing globenewswire.com - March 28 at 7:05 AM
	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference globenewswire.com - February 28 at 4:01 PM
	Xilio Therapeutics Inc XLO morningstar.com - February 27 at 11:45 PM
	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference finance.yahoo.com - January 31 at 7:02 PM
	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies finance.yahoo.com - January 8 at 8:37 AM
	Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines seekingalpha.com - December 28 at 10:46 PM
	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data finance.yahoo.com - December 7 at 8:38 AM
	Xilio Therapeutics GAAP EPS of -$0.61 msn.com - November 10 at 1:22 PM
	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results finance.yahoo.com - November 9 at 4:36 PM
	Promising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio Therapeutics markets.businessinsider.com - November 8 at 12:37 AM
	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors finance.yahoo.com - November 3 at 1:34 PM
	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting finance.yahoo.com - October 31 at 12:03 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BriaCell Therapeutics

NASDAQ:BCTX

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Satsuma Pharmaceuticals

NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Unicycive Therapeutics

NASDAQ:UNCY

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Xilio Therapeutics

NASDAQ:XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial